GDNF Parkinson's race: Amgen plans Phase I with Medtronic device; Genentech licenses neurturin.
AMGEN GDNF PHASE I TRIALS WILL EXAMINE INTRAVENTRICULAR DOSING as well as standard analysis of safety and tolerability of glial-derived neurotrophic factor. The early-stage Parkinson's disease drug is nearing the start of human trials, and Phase I studies in patients with modest to moderately severe Parkinson's are projected to begin later this year, the company told the financial community at a March 25 meeting in New York City.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth